FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2507308216> ?p ?o ?g. }

• W2507308216 abstract "Recent study has shown that N-end rule pathway, an ubiquitin dependent proteolytic system, counteracts cell death by degrading many antisurvival protein fragments like BCLxL, BRCA1, RIPK1, etc. Inhibition of the N-end rule pathway can lead to metabolic stabilization of proapoptotic protein fragments like RIPK1, thereby sensitizing cells to programmed cell death. Receptor interacting serine-threonine protein kinase-1 (RIPK1) is one of the upstream regulators of programmed necrosis known as necroptosis. Necroptosis is particularly gaining attention of cancer biologists as it provides an alternate therapeutic modality to kill cancer cells, which often evolve multiple strategies to circumvent growth inhibition by apoptosis. Utilizing the over expression of biotin receptor in cancer cells, herein, we report that coadministration of synthetic hetero-bivalent N-end rule inhibitor RFC11 and anticancer drug shikonin solubilized in a stable biotin receptor-targeted liposome exhibited significant synergistic antitumor effect in both subcutaneous and orthotopic mouse colon tumor model through induction of necroptosis with distinctive upregulation of RIPK1. Besides developing a newly targeted formulation for necroptosis induction, this report is the first in vivo evidence demonstrating that potent inhibition of N-end rule pathway can enhance therapeutic efficacy of conventional chemotherapeutics. Recent study has shown that N-end rule pathway, an ubiquitin dependent proteolytic system, counteracts cell death by degrading many antisurvival protein fragments like BCLxL, BRCA1, RIPK1, etc. Inhibition of the N-end rule pathway can lead to metabolic stabilization of proapoptotic protein fragments like RIPK1, thereby sensitizing cells to programmed cell death. Receptor interacting serine-threonine protein kinase-1 (RIPK1) is one of the upstream regulators of programmed necrosis known as necroptosis. Necroptosis is particularly gaining attention of cancer biologists as it provides an alternate therapeutic modality to kill cancer cells, which often evolve multiple strategies to circumvent growth inhibition by apoptosis. Utilizing the over expression of biotin receptor in cancer cells, herein, we report that coadministration of synthetic hetero-bivalent N-end rule inhibitor RFC11 and anticancer drug shikonin solubilized in a stable biotin receptor-targeted liposome exhibited significant synergistic antitumor effect in both subcutaneous and orthotopic mouse colon tumor model through induction of necroptosis with distinctive upregulation of RIPK1. Besides developing a newly targeted formulation for necroptosis induction, this report is the first in vivo evidence demonstrating that potent inhibition of N-end rule pathway can enhance therapeutic efficacy of conventional chemotherapeutics." @default.
• W2507308216 created "2016-09-16" @default.
• W2507308216 creator A5015756555 @default.
• W2507308216 creator A5025250843 @default.
• W2507308216 date "2016-01-01" @default.
• W2507308216 modified "2023-09-23" @default.
• W2507308216 title "N-end rule pathway inhibition assists colon tumor regression via necroptosis" @default.
• W2507308216 cites W1489931243 @default.
• W2507308216 cites W1546068374 @default.
• W2507308216 cites W1850224498 @default.
• W2507308216 cites W1935205737 @default.
• W2507308216 cites W1964547598 @default.
• W2507308216 cites W1967393143 @default.
• W2507308216 cites W1980005294 @default.
• W2507308216 cites W1985214621 @default.
• W2507308216 cites W1990636775 @default.
• W2507308216 cites W1994282868 @default.
• W2507308216 cites W2008408444 @default.
• W2507308216 cites W2010802988 @default.
• W2507308216 cites W2013765163 @default.
• W2507308216 cites W2016034696 @default.
• W2507308216 cites W2017367722 @default.
• W2507308216 cites W2021363994 @default.
• W2507308216 cites W2023122823 @default.
• W2507308216 cites W2023376720 @default.
• W2507308216 cites W2034269086 @default.
• W2507308216 cites W2047389902 @default.
• W2507308216 cites W2048588387 @default.
• W2507308216 cites W2050753030 @default.
• W2507308216 cites W2060601646 @default.
• W2507308216 cites W2062181861 @default.
• W2507308216 cites W2065472817 @default.
• W2507308216 cites W2070733259 @default.
• W2507308216 cites W2071056869 @default.
• W2507308216 cites W2082828565 @default.
• W2507308216 cites W2089769997 @default.
• W2507308216 cites W2094572545 @default.
• W2507308216 cites W2098933735 @default.
• W2507308216 cites W2117692326 @default.
• W2507308216 cites W2123504406 @default.
• W2507308216 cites W2136470827 @default.
• W2507308216 cites W2150048195 @default.
• W2507308216 cites W2153617834 @default.
• W2507308216 cites W2159006827 @default.
• W2507308216 cites W2161830466 @default.
• W2507308216 cites W2165805342 @default.
• W2507308216 cites W2166802900 @default.
• W2507308216 cites W2316974258 @default.
• W2507308216 cites W4214850937 @default.
• W2507308216 cites W4327849144 @default.
• W2507308216 cites W95809759 @default.
• W2507308216 doi "https://doi.org/10.1038/mto.2016.20" @default.
• W2507308216 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4980110" @default.
• W2507308216 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27556106" @default.
• W2507308216 hasPublicationYear "2016" @default.
• W2507308216 type Work @default.
• W2507308216 sameAs 2507308216 @default.
• W2507308216 citedByCount "14" @default.
• W2507308216 countsByYear W25073082162017 @default.
• W2507308216 countsByYear W25073082162018 @default.
• W2507308216 countsByYear W25073082162019 @default.
• W2507308216 countsByYear W25073082162020 @default.
• W2507308216 countsByYear W25073082162021 @default.
• W2507308216 countsByYear W25073082162022 @default.
• W2507308216 countsByYear W25073082162023 @default.
• W2507308216 crossrefType "journal-article" @default.
• W2507308216 hasAuthorship W2507308216A5015756555 @default.
• W2507308216 hasAuthorship W2507308216A5025250843 @default.
• W2507308216 hasBestOaLocation W25073082161 @default.
• W2507308216 hasConcept C121608353 @default.
• W2507308216 hasConcept C184235292 @default.
• W2507308216 hasConcept C185592680 @default.
• W2507308216 hasConcept C190283241 @default.
• W2507308216 hasConcept C2776550021 @default.
• W2507308216 hasConcept C31573885 @default.
• W2507308216 hasConcept C502942594 @default.
• W2507308216 hasConcept C54355233 @default.
• W2507308216 hasConcept C55493867 @default.
• W2507308216 hasConcept C62478195 @default.
• W2507308216 hasConcept C86803240 @default.
• W2507308216 hasConcept C94030615 @default.
• W2507308216 hasConcept C95444343 @default.
• W2507308216 hasConcept C96232424 @default.
• W2507308216 hasConceptScore W2507308216C121608353 @default.
• W2507308216 hasConceptScore W2507308216C184235292 @default.
• W2507308216 hasConceptScore W2507308216C185592680 @default.
• W2507308216 hasConceptScore W2507308216C190283241 @default.
• W2507308216 hasConceptScore W2507308216C2776550021 @default.
• W2507308216 hasConceptScore W2507308216C31573885 @default.
• W2507308216 hasConceptScore W2507308216C502942594 @default.
• W2507308216 hasConceptScore W2507308216C54355233 @default.
• W2507308216 hasConceptScore W2507308216C55493867 @default.
• W2507308216 hasConceptScore W2507308216C62478195 @default.
• W2507308216 hasConceptScore W2507308216C86803240 @default.
• W2507308216 hasConceptScore W2507308216C94030615 @default.
• W2507308216 hasConceptScore W2507308216C95444343 @default.
• W2507308216 hasConceptScore W2507308216C96232424 @default.
• W2507308216 hasLocation W25073082161 @default.
• W2507308216 hasLocation W25073082162 @default.
• W2507308216 hasLocation W25073082163 @default.

• next